Moderna (MRNA) Invested Capital (2019 - 2026)

Moderna has reported Invested Capital for 8 years, with the latest figure at $37.0 million in Q2 2026.

• Invested Capital for Q2 2026 came in at $37.0 million, down 37.29% year-over-year; the trailing twelve-month figure through Jun 2026 was $183.0 million (down 78.19% YoY), and the FY2025 annual result was $45.0 million, down 27.42% from the prior year.
• Invested Capital fell to $37.0 million in Q2 2026, from $44.0 million in the prior quarter.
• Over five years, Invested Capital peaked at $1.1 billion in Q3 2022 and troughed at $37.0 million in Q2 2026.
• A 5-year average of $515.2 million and a median of $575.5 million in 2023 frame the typical range for Invested Capital.
• The widest annual swing landed in 2022, when Invested Capital soared 340.44%; it then plunged 91.3% in 2025.
• A 5-year view of Invested Capital shows it stood at $1.1 billion in 2022, then tumbled by 46.41% to $575.0 million in 2023, then slumped by 89.22% to $62.0 million in 2024, then slipped by 27.42% to $45.0 million in 2025, then decreased by 17.78% to $37.0 million in 2026.
• Per Business Quant data, the three most recent Invested Capital figures were $37.0 million in Q2 2026, $44.0 million in Q1 2026, and $45.0 million in Q4 2025.